Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2023 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there
are no false representations, misleading statements or material omissions contained in
this announcement and accept legal responsibility for the truthfulness, accuracy and
completeness of the contents hereof.
IMPORTANT NOTICE:
The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this
quarterly report, and that there are no false representations, misleading statements or material
omissions contained herein, and severally and jointly accept legal responsibility.
The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-
charge of the accounting department (the head of the accounting department) hereby warrant the
truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
Whether the third quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
From the
For the Reporting
beginning of the
Period
Item YoY change (%) year to the end of YoY change (%)
(From July to
the Reporting
September)
Period
Revenues 3,931,515,787.21 -11.59 12,651,257,386.44 -2.77
Net profit attributable to
Shareholders of the listed 268,214,419.85 -17.55 1,083,649,154.75 -3.81
company
Net profit attributable to
Shareholders of the listed
267,477,595.49 -14.37 1,049,221,737.67 -6.01
company after deduction of
extraordinary gains and losses
1 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Net cash flow from operating
N/A N/A 2,459,851,744.70 -5.72
activities
Basic earnings per share
0.1418 -18.87 0.5682 -5.03
(RMB/share)
Diluted earnings per share
0.1412 -18.83 0.5663 -5.17
(RMB/share)
Weighted average return on Decreased by 0.80 Decreased by1.16
1.93 8.22
net assets (%) percentage points percentage points
Change in the
ending amount of
As at the end of the
As at the end of the previous year the Reporting
Reporting Period
Period to that of
the previous (%)
Total assets 35,769,669,256.09 35,729,253,651.41 0.11
Net assets attributable to
Shareholders of the listed 13,337,938,211.52 13,121,820,410.55 1.65
company
Notes: 1. The “Reporting Period” refers to the three-month period from the beginning to the end of this quarter,
the same below.
2. From January to September 2023, the Company Chemical pharmaceuticals realized revenues of
RMB6,572 million, representing a YoY decrease of 9.20%, among which, RMB1,112 million were from
respiratory formulation products, representing a YoY increase of 28.98%; RMB400 million were from anti-
infection products, representing a YoY decrease of 65.23%; RMB2,279 million were from gastroenterology
products, representing a YoY decrease of 12.93%; RMB2,188 million were from gonadotropic hormones,
representing a YoY increase of 4.94%; and RMB430 million were from psychiatry products, representing a
YoY increase of 7.60%. APIs and intermediates products realized revenues of RMB3,970 million, representing
a YoY decrease of 2.07%. Traditional Chinese Medicine products realized revenues of RMB1,291 million,
representing a YoY increase of 49.48%. Diagnostic reagents and equipment products realized revenues of
RMB468 million, representing a YoY decrease of 6.88%. Health care products realized revenues of RMB132
million, representing a YoY increase of 60.12%. Biological products realized revenues of RMB113 million,
representing a YoY decrease of 31.09%.
3. From January to September 2023, the Company realized net profit attributable to shareholders of the
parent of RMB1,084 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profit
attributable to shareholders of the parent of approximately RMB612 million, representing a YoY decrease of
approximately 4.17%, and the impact of Livzon MAB on the net profit attributable to shareholders of the parent
was approximately negative RMB412 million.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
From the beginning of the
For the
Item year to the end of the
Reporting Period
Reporting Period
Gains and losses on disposal of non-current assets 141,880.83 -200,478.63
2 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Government grants as included in the profit or loss for the
Period, however, except for those which are closely related to
the normal business of an enterprise, comply with thepolicies of 25,392,502.84 148,737,247.12
the State and are continuously entitled with specific amount or
quantity according to certain standards
Gains and losses on fair value changes incurred from financial
assets held for trading, derivative financial assets, financial
liabilities held for trading and derivative financial liabilities, and
investment income on disposal of financial assets held for
-21,111,799.30 -66,463,191.33
trading, derivative financial assets, financial liabilities held for
trading, derivative financial liabilities and other debt
investments, except for effective hedging activities related to the
ordinary operating business of the Company
Other non-operating income and expenses excluding the above
-11,850,546.09 -17,463,124.32
items
Less: Effect of income tax 1,076,795.55 13,107,981.50
Effect of minority equity (after tax) -9,241,581.63 17,075,054.26
Total 736,824.36 34,427,417.08
Explanations for classifying items of extraordinary gains and losses defined in the Explanatory
Announcement No. 1 for Public Company Information Disclosures –Extraordinary Gains or Losses as
items of recurring gains or losses.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof
□Applicable √N/A
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons
Thereof
Unit: Yuan Currency: RMB
Change in
30 September 31 December
Balance Sheet proportion Main Reason
2023 2022
（%）
Mainly due to fluctuations in
Financial assets held for
73,193,659.40 109,015,664.98 -32.86 market value of the securities
trading
investment held.
Mainly due to an increase in
Non-current assets due large-denomination of
362,830,383.78 54,048,611.11 571.30
within one year deposit maturing within one
year.
Mainly due to the production
lines of new factories and
Construction in
562,135,145.68 811,300,068.96 -30.71 workshops of the
progress
subsidiaries transferred to
fixed assets.
Mainly due to the changes in
Financial liabilities held
10,966,528.06 755,634.43 1,351.30 fair value of foreign currency
for trading
forward contracts.
Mainly due to some contract
performance obligations
Contract liabilities 75,564,862.24 292,977,730.74 -74.21 during the current period,
which satisfies the
conditions for revenues
3 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
recognition and results in the
carrying forward of revenue.
Mainly due to the decrease
Other current liabilities 45,432,846.70 101,276,714.35 -55.14
in estimated refund payable.
Mainly due to the decrease
in lease contracts signed
Lease liabilities 14,438,999.56 23,482,486.07 -38.51
during the period, leading to
a decrease in lease payables.
Mainly due to the repurchase
Treasury shares 564,252,205.84 347,176,561.29 62.53 of A shares of the Company
during the Period.
Change in
January to January to
Statement of Income proportion Main Reason
September 2023 September 2022
（%）
Mainly due to fluctuations in
Gains from changes in
-46,003,628.22 -86,989,533.83 N/A market value of the securities
fair values
investment held.
Mainly due to changes in the
aging of accounts
receivables, leading to the
Credit impairment loss -17,737,505.85 -9,508,656.53 N/A
corresponding increase in
expected credit loss during
the Period.
Mainly due to gains incurred
Gains from disposal of
-200,478.63 1,121,679.66 -117.87 from disposal of fixed assets
assets
during the previous period.
Mainly due to the increase in
expenditure of charitable
Non-operating expenses 23,765,998.31 13,738,456.89 72.99 donation for the period as
compared with the previous
period.
Mainly due to changes in the
fair value of other equity
instrument investments and
Other comprehensive exchange rate fluctuations
-22,658,520.87 80,412,282.94 -128.18
income –net of tax resulting in changes in
translation differences of
foreign currency financial
statements.
Change in
January to January to
Cash Flow Statement proportion Main Reason
September 2023 September 2022
（%）
Mainly due to the issuance
of GDRs (Global Depository
Net cash flows from
-1,987,651,014.91 873,841,344.96 -327.46 Receipts) and the increase in
financing activities
loans in the same period of
the previous year.
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
Total number of holders of ordinary Total number of holders of preferred
shares as of the end of the Reporting 79,393 shares with restored voting rights as of the 0
Period end of the Reporting Period (if any)
4 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Shareholdings of the top 10 shareholders
Number of Pledge, mark or lock-up
Nature of Number of Percentage shares held
Name of shareholder
shareholder shares held (%) with selling Share
restrictions status
Number
Domestic non-
Shenzhen Baiyeyuan Investment Co., Ltd.
state-owned 895,653,653 46.83 0 Pledge 75,679,725
(深圳市百业源投资有限公司)
legal person
Hong Kong Securities Clearing Company
Unknown 94,148,526 4.92 0 Unknown
Limited
Foreign legal
Might Seasons Limited 35,929,699 1.88 0 Unknown
person
Perseverance Asset Management L.L.P–
Unknown 16,561,348 0.87 0 Unknown
Gaoyi Xiaofeng No. 2 Zhixin Fund
China Foreign Economy and Trade Trust
Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Unknown 16,177,148 0.85 0 Unknown
Hongyuan Collection Fund Trust Plan
Huaxia Life Insurance Co., Ltd. - Own
Unknown 12,729,218 0.67 0 Unknown
fund
Abu Dhabi Investment Authority Unknown 10,232,971 0.54 0 Unknown
Bank of Shanghai Co., Ltd.－Yinhua CSI
Innovative Drug Industry Trading Open- Unknown 9,656,996 0.50 0 Unknown
end Index Securities Investment Fund
Agricultural Bank of China Limited -CSI
500 Exchange Traded Index Securities Unknown 8,405,974 0.44 0 Unknown
Investment Fund
CPIC Fund -China Pacific Life Insurance
Co., Ltd. -with-profit insurance-CPIC
Fund China Pacific Life Equity Relative Unknown 7,558,834 0.40 0 Unknown
Income (Guaranteed Dividend) single
assets management plan
Shareholdings of the top 10 shareholders without selling restrictions
Number of tradable shares Class and number of shares
Name of shareholder held without selling
Class of shares Number
restrictions
Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源 Ordinary shares
895,653,653 895,653,653
投资有限公司) denominated in Renminbi
Ordinary shares
Hong Kong Securities Clearing Company Limited 94,148,526 94,148,526
denominated in Renminbi
Ordinary shares
Might Seasons Limited 35,929,699 35,929,699
denominated in Renminbi
Perseverance Asset Management L.L.P–Gaoyi Xiaofeng Ordinary shares
16,561,348 16,561,348
No. 2 Zhixin Fund denominated in Renminbi
China Foreign Economy and Trade Trust Co., Ltd.–Foreign
Ordinary shares
Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust 16,177,148 16,177,148
denominated in Renminbi
Plan
Ordinary shares
Huaxia Life Insurance Co., Ltd. - Own fund 12,729,218 12,729,218
denominated in Renminbi
Ordinary shares
Abu Dhabi Investment Authority 10,232,971 10,232,971
denominated in Renminbi
Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug
Ordinary shares
Industry Trading Open-end Index Securities Investment 9,656,996 9,656,996
denominated in Renminbi
Fund
Agricultural Bank of China Limited -CSI 500 Exchange Ordinary shares
8,405,974 8,405,974
Traded Index Securities Investment Fund denominated in Renminbi
CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-
profit insurance-CPIC Fund China Pacific Life Equity Ordinary shares
7,558,834 7,558,834
Relative Income (Guaranteed Dividend) single assets denominated in Renminbi
management plan
5 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
There was no connection or acting-in-concert relationship between Shenzhen
Description of connection or acting-in-concert relationship Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company,
of the above shareholders and other shareholders; whether there is connection or acting-in-concert
relationship among other shareholders is unknown.
Description of the participation of the top 10 shareholders
and the top 10 shareholders without selling restrictions in
N/A
margin financing and securities lending and refinancing
business (if any)
As of the end of the Reporting Period, the special repurchase account of the
Description of the special repurchase account among the Company (Special securities repurchase account of Joincare Pharmaceutical
top 10 shareholders Group Industry Co., Ltd.) owned 46,513,711 shares in total, accounting for
2.43%.
III. OTHER REMINDERS
Other important information regarding the Company’s operations during the Reporting Period to which
investors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
6 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Consolidated Balance Sheet
30 September 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
Item 30 September 2023 31 December 2022
Current assets:
Cash and bank balances 14,411,629,365.32 14,808,488,110.96
Financial assets held for trading 73,193,659.40 109,015,664.98
Notes receivable 2,081,418,640.69 1,959,985,016.85
Accounts receivable 2,939,748,117.45 3,103,758,850.15
Receivables financing
Prepayments 421,312,293.00 364,265,142.57
Other receivables 64,768,235.54 52,535,740.14
Including: Interests receivable
Dividends receivable
Inventories 2,717,381,235.93 2,561,869,999.57
Contract assets
Assets held-for-sale
Non-current assets due within one year 362,830,383.78 54,048,611.11
Other current assets 166,958,865.87 163,539,900.32
Total current assets 23,239,240,796.98 23,177,507,036.65
Non-current assets:
Debt investment
Other debt investment
Long-term receivables
Long-term equity investment 1,446,149,124.12 1,419,882,594.59
Other equity instrument investments 1,141,445,217.03 1,193,958,879.05
Other non-current financial assets
Investment properties 6,191,475.43 6,191,475.43
Fixed assets 5,683,766,148.57 5,265,200,110.91
Construction in progress 562,135,145.68 811,300,068.96
Productive biological assets
Oil and gas assets
Right-of-use assets 35,342,825.78 41,843,133.97
Intangible assets 701,729,275.21 802,115,125.75
Development expenditures 424,798,732.53 428,284,884.17
Goodwill 636,339,503.82 614,468,698.73
Long-term prepaid expenses 293,226,959.06 277,867,716.95
Deferred income tax assets 531,621,736.93 533,861,743.26
Other non-current assets 1,067,682,314.95 1,156,772,182.99
Total non-current assets 12,530,428,459.11 12,551,746,614.76
Total assets 35,769,669,256.09 35,729,253,651.41
Current liabilities:
Short-term loans 1,776,144,861.11 2,126,050,615.06
Financial liabilities held for trading 10,966,528.06 755,634.43
Notes payable 1,530,559,158.55 1,635,906,989.22
Accounts payable 906,022,129.06 943,905,580.91
Receipts in advance
Contract liabilities 75,564,862.24 292,977,730.74
Employee benefits payable 499,860,346.48 573,010,571.46
Taxes payable 307,862,506.00 337,702,273.73
Other payables 3,752,472,841.38 3,680,334,360.88
Including: Interests payable
7 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Dividends payable 14,641,641.87 12,252,074.84
Liabilities held-for-sale
Non-current liabilities due within one year 71,269,180.31 63,077,260.98
Other current liabilities 45,432,846.70 101,276,714.35
Total current liabilities 8,976,155,259.89 9,754,997,731.76
Non-current liabilities:
Long-term loans 3,940,728,610.19 3,230,844,042.88
Bonds payable
Lease liabilities 14,438,999.56 23,482,486.07
Long-term payables
Long-term payroll payable
Estimated liabilities
Deferred income 412,897,139.98 384,537,267.55
Deferred income tax liabilities 241,853,901.75 231,164,425.48
Other non-current liabilities 90,000,000.00 84,000,000.00
Total non-current liabilities 4,699,918,651.48 3,954,028,221.98
Total liabilities 13,676,073,911.37 13,709,025,953.74
Owner's equity (or shareholder's equity):
Paid-in capital (or Share capital) 1,912,448,568.00 1,929,189,374.00
Other equity instruments
Including: Preferred shares
Perpetual debts
Capital reserve 2,044,380,284.45 2,343,693,215.99
Less: Treasury shares 564,252,205.84 347,176,561.29
Other comprehensive income 5,710,233.93 4,704,473.53
Special reserve
Surplus reserve 734,905,013.97 734,766,581.50
Undistributed profits 9,204,746,317.01 8,456,643,326.82
Total owner's equity (or shareholder's equity)
13,337,938,211.52 13,121,820,410.55
attributable to the parent
Minority shareholder's equity 8,755,657,133.20 8,898,407,287.12
Total owner's equity (or shareholder's equity) 22,093,595,344.72 22,020,227,697.67
Total liabilities and owner's equity (or
35,769,669,256.09 35,729,253,651.41
shareholder's equity)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
8 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Consolidated Income Statement
From January to September, 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First three quarters First three quarters
Item (January to September) (January to September)
of 2023 of 2022
I. Total revenues 12,651,257,386.44 13,011,966,738.16
Including: Operating revenues 12,651,257,386.44 13,011,966,738.16
II. Total operating costs 9,992,088,727.85 10,347,452,908.46
Including: Operating costs 4,836,588,741.76 4,590,752,440.39
Tax and surcharges 150,278,107.37 148,072,490.55
Selling expenses 3,428,038,993.64 3,893,351,191.76
Administrative expenses 680,009,158.86 813,143,493.11
R&D expenses 1,211,596,866.40 1,232,505,100.33
Financial expenses -314,423,140.18 -330,371,807.68
Including: Interest expenses 106,424,878.84 95,844,022.98
Interest income 373,189,603.11 296,268,948.39
Add: Other income 150,725,832.49 142,661,731.19
Investments income (“-” for loss) 58,569,845.80 48,386,584.36
Including: Income from investments
57,873,393.21 52,468,548.10
in associates and joint ventures
Gains from derecognition of financial
assets at amortized cost
Gains from net exposure hedges (“-”
for loss)
Gains from changes in fair values
-46,003,628.22 -86,989,533.83
(“-” for loss)
Credit impairment loss (“-” for loss) -17,737,505.85 -9,508,656.53
Assets impairment loss (“-” for loss) -108,440,945.45 -142,159,872.24
Gains from disposal of assets (“-” for
-200,478.63 1,121,679.66
loss)
III. Operating profit (“-” for loss) 2,696,081,778.73 2,618,025,762.31
Add: Non-operating income 6,302,873.99 4,995,275.26
Less: Non-operating expenses 23,765,998.31 13,738,456.89
IV. Total profit (“-” for loss) 2,678,618,654.41 2,609,282,580.68
Less: Income tax expenses 433,823,342.57 408,012,299.49
V. Net profit (“-” for loss) 2,244,795,311.84 2,201,270,281.19
(I) Classified by business continuity
1. Net profit from continuing operation
2,244,795,311.84 2,201,270,281.19
(“-” for loss)
2. Net profit from discontinued
operation (“-” for loss)
(II) Classified by ownership
1.Net profit attributable to shareholders
1,083,649,154.75 1,126,561,953.23
of the parent company (“-” for loss)
2.Profit and loss of minority
1,161,146,157.09 1,074,708,327.96
shareholders (“-” for loss)
VI. Other comprehensive income, net of
-22,658,520.87 80,412,282.94
tax
(I) Other comprehensive income
attributable to owners of the parent, net 1,005,760.40 31,984,064.97
of tax
9 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
1. Other comprehensive income that
-31,488,647.75 12,029,097.03
cannot be reclassified into profit or loss
(1) Changes from remeasurement of
defined benefit plans
(2) Other comprehensive income that
cannot be reclassified into profit or loss 0.00 1,173,144.60
under the equity method
(3) Changes in fair value of
-31,488,647.75 10,855,952.43
investments in other equity instruments
(4) Changes in fair value of the
enterprise's own credit risks
2. Other comprehensive income that
32,494,408.15 19,954,967.94
will be reclassified into profit or loss
(1) Other comprehensive income that
can be reclassified into profit or loss under 164,225.81 0.00
the equity method
(2) Changes in fair value of other
debt investments
(3) Amount of financial assets
reclassified into other comprehensive
income
(4) Provision for credit impairment of
other debt investments
(5) Reserve for cash flow hedges
(6) Exchange translation differences
on financial statements denominated in 32,330,182.33 19,954,967.94
foreign currencies
(7) Others
(II) Other comprehensive income
attributable to minority shareholders, net -23,664,281.27 48,428,217.97
of tax
VII. Total comprehensive income 2,222,136,790.97 2,281,682,564.13
(I) Total comprehensive income
1,084,654,915.15 1,158,546,018.20
attributable to owners of the parent
(II) Total comprehensive income
1,137,481,875.82 1,123,136,545.93
attributable to minority shareholders
VIII. Earnings per share:
(I) Basic earnings per share (RMB/share) 0.5682 0.5983
(II) Diluted earnings per share
0.5663 0.5971
(RMB/share)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
10 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Consolidated Cash Flow Statement
From January to September, 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First three quarters First three quarters
Item (January to September) (January to September)
of 2023 of 2022
I. Cash flows from operating activities:
Cash received from sales of goods or rendering of
13,510,230,759.20 13,705,807,329.89
services
Tax refunds received 141,490,762.85 219,263,256.92
Other cash received related to operating activities 620,955,869.98 536,180,845.96
Subtotal of cash inflow from operating
14,272,677,392.03 14,461,251,432.77
activities
Cash paid for goods and services 4,573,141,561.87 4,180,212,054.68
Cash paid to and on behalf of employees 1,764,671,591.22 1,797,221,409.89
Payments of all types of taxes 1,416,153,712.56 1,293,188,165.95
Other cash paid related to operating activities 4,058,858,781.68 4,581,637,269.28
Subtotal of cash outflow in operating activities 11,812,825,647.33 11,852,258,899.80
Net cash flows from operating activities 2,459,851,744.70 2,608,992,532.97
II. Cash flows from investing activities:
Cash received from disposal of investments 390,344,459.46 216,970,980.42
Cash received from investment income 70,124,524.03 121,905,782.77
Net cash received from disposal of fixed assets,
8,042,426.01 1,307,684.20
intangible assets and other long-term assets
Net cash received from disposal of subsidiaries
and other business units
Other cash received related to investing activities 297,590,000.00 13,356,765.87
Subtotal of cash inflows from investing
766,101,409.50 353,541,213.26
activities
Cash paid for purchase and construction of fixed
753,228,828.13 975,980,046.68
assets, intangible assets and other long-term assets
Cash paid to acquire investments 439,136,113.68 37,995,968.80
Net cash paid for acquisition of subsidiaries and
22,461,951.59 0.00
other business units
Other cash paid related to investing activities 227,027,492.56 226,494,395.22
Subtotal of cash outflows in investing activities 1,441,854,385.96 1,240,470,410.70
Net cash flows from investing activities -675,752,976.46 -886,929,197.44
III. Cash flows from financing activities:
Cash received from capital contribution 18,056,784.20 719,365,346.09
Including: Cash received from investment by
6,700,000.00 0.00
minority interests of subsidiaries
Cash received from borrowings 3,347,170,168.70 5,297,022,796.00
Other cash received related to financing activities 20,000,000.00 303,958,487.50
Subtotal of cash inflows from financing
3,385,226,952.90 6,320,346,629.59
activities
Cash repayments of amounts borrowed 2,592,352,425.04 3,504,080,892.47
Cash payments for interest expenses and
1,570,166,936.38 1,314,118,888.43
distribution of dividends or profits
Including: Dividends and profit paid to minority
1,120,761,303.69 960,193,396.67
interests of subsidiaries
Other cash payments related to financing
1,210,358,606.39 628,305,503.73
activities
11 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 Third Quarterly Report
Subtotal of cash outflows from financing
5,372,877,967.81 5,446,505,284.63
activities
Net cash flows from financing activities -1,987,651,014.91 873,841,344.96
IV. Effect of exchange rate changes on cash and
71,991,155.94 227,244,304.84
cash equivalents
V. Net increase in cash and cash equivalents -131,561,090.73 2,823,148,985.32
Add: Opening balance of cash and cash
14,178,465,686.40 11,697,518,141.18
equivalents
VI. Closing balance of cash and cash equivalents 14,046,904,595.67 14,520,667,126.50
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
(Ⅲ) Implementation of new accounting standards or interpretations of standards, for the third time from
2023 involves adjustments to the financial statements at the beginning of the year
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
25 October, 2023
12 / 12
